Novo Nordisk (NVO) (OTCPK:NONOF) announced on Sunday that its popular weight loss drug Wegovy resulted in more than a 50% decrease in serious heart issues such as stroke compared to Eli Lilly’s (NYSE:LLY) competing drug
Welcome to AI Investor Picks, your trusted source for investment insights, financial strategies, and business opportunities. We are dedicated to providing cutting-edge information and analysis on a wide range of investment topics, including stocks, cryptocurrency, real estate, finance, and much more.
